Fenfluramine is commonly used as an add-on therapy for patients with two specific, severe forms of epilepsy: Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). It is generally applied in contexts where patients experience symptoms that create noticeable physiological strain and heightened neurological activity that interfere with daily functioning.

Quick Fact: Relevant for Intractable Seizure Activity

This medication is primarily relevant across domains where additional symptomatic support is needed. It is considered relevant for managing the refractory seizure patterns associated with DS and LGS, and is applied in conditions marked by increased physiological stress. Минифаж plays a role in managing symptoms related to heightened neurological activity, and is commonly used to help with frequent convulsive seizures and symptoms that interfere with daily functioning.

This applied support contributes to easing the overall symptom load and is relevant for easing manifestations that become more disruptive during flare-ups. In situations where symptoms are managed, the medication supports patients during episodes of heightened discomfort. It may assist with maintaining functional stability, which helps improve day-to-day comfort during symptomatic periods.

Who can and cannot use Минифаж?

Eligibility for Минифаж (Fenfluramine) is strictly governed by regulatory labeling, defining the specific patient population allowed to use the drug and those who are absolutely excluded.

Approved Populations

Минифаж is approved as an add-on treatment for patients 2 years of age and older with seizures associated with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS). Use is conditional on enrollment in a Risk Evaluation and Mitigation Strategy (REMS) or equivalent Controlled Access Program, which mandates periodic cardiac monitoring.

Absolute Contraindications

The medicine must not be used by patients with the following conditions:

• Aortic or Mitral Valvular Heart Disease or Pulmonary Arterial Hypertension (PAH).
• Known hypersensitivity to fenfluramine or its excipients.
• Use of a Monoamine Oxidase Inhibitor (MAOI) currently or within the past 14 days.

️ Use Restrictions

Use is generally not recommended in children under 2 years of age (safety not established) and in women who are breastfeeding. Special consideration is required for patients with moderate or severe hepatic or renal impairment, as the dosage may need adjustment or use may be restricted, particularly when taken with the concomitant drug stiripentol.

Interactions with other medicines and products

The official interaction profile for Минифаж (Fenfluramine) is structured around specific pharmacokinetic changes and pharmacodynamic risks documented in government regulatory sources.

---

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the high risk of Serotonin Syndrome. Regulatory labeling mandates that Fenfluramine must not be administered within 14 days of discontinuing or initiating MAOI use.

---

Exposure-Modifying Interactions

Fenfluramine plasma exposure is documented to be significantly increased by co-administering Stiripentol, Cannabidiol (CBD), Strong CYP1A2 Inhibitors, or Strong CYP2D6 Inhibitors. These pharmacokinetic interactions necessitate a formal reduction in the maximum recommended daily dosage of Fenfluramine, as defined in the official prescribing information.

---

Pharmacodynamic Risks

Additive effects are documented with several substance categories. Concomitant use with other Serotonergic Medicinal Products (including SSRIs, SNRIs, triptans, and tramadol) carries an official risk of Serotonin Syndrome. Combining Fenfluramine with Alcohol or other Central Nervous System (CNS) Depressants may lead to potentiated CNS depressant effects.

---

Administration Notes and Population Constraints

Fenfluramine can be taken with or without food as no clinically relevant food effect on exposure is documented. A specific dosage reduction is recommended for patients with Severe Renal Impairment. Use with Stiripentol is not recommended in patients with Severe Hepatic Impairment.

How Минифаж Works

Минифаж functions as a reversible, highly selective inhibitor of the intracellular enzyme Farnesyl Pyrophosphate Synthase (FPPS). The molecule achieves its effect by binding directly to the enzyme’s active site. This molecular interaction prevents the conversion of its substrate, geranyl pyrophosphate (GPP), into farnesyl pyrophosphate (FPP), thereby defining the primary biological target within the mevalonate pathway.

The consequent reduction in intracellular FPP levels limits the necessary precursor for protein prenylation. This inhibition cascade leads to decreased farnesylation and geranylgeranylation of small GTPase signaling proteins (e.g., Rho, Rac, and Rab). By blocking this post-translational modification, Минифаж modulates the membrane localization and activation of these regulatory GTPases, altering their intracellular signaling activity.

This systematic blockage disrupts several downstream pathways, including those governing cytoskeletal arrangement and cellular processes, resulting in an overall modulation of protein function and cellular metabolism at the system level.

How to Use Минифаж

The administration of Fenfluramine (Минифаж) follows procedural guidelines which focus on precise, weight-based dosing and defined administration conditions.

---

Administration Protocol Summary

Instruction	Guideline
Route of Administration	The medicine is an oral solution taken by mouth. It is also compatible with administration through gastric and nasogastric feeding tubes.
Dosing Schedule	The regimen is calculated based on body weight (mg/kg), administered twice daily (BID). The starting dose is typically 0.1 mg/kg per day, divided over two doses.
Titration and Limits	The dose is generally increased (titrated) on a weekly schedule. The total daily dose has specific limits, such as a maximum of 26 mg (without concomitant stiripentol and clobazam) or 17 mg (with concomitant stiripentol and clobazam).
Administration Tool	The dose must be accurately measured using only the calibrated oral measuring device provided, not a household spoon. The solution can be taken with or without food.
Discontinuation	The medication requires a gradual dose reduction (tapering) when ending treatment; abrupt cessation is not permitted.

---

Use-Context Constraints

Минифаж is approved for use in patients 2 years of age and older. The maximum permissible daily dose is constrained by the presence of concomitant anti-epileptic therapy and must be adjusted downward in cases of severe renal impairment or severe hepatic impairment. The overall use protocol is structured around a continuous, long-term approach with strict adherence to the calculated weight-based dosage to maintain the defined therapeutic use pattern.

Research evidence / Overview of studies for Минифаж

---

Evidence for use in Dravet Syndrome (DS)

Research evidence for Минифаж (Fenfluramine) includes short-term, randomized, controlled trials (RCTs). These studies were designed to explore how the study drug compared to a placebo (an inactive treatment) when evaluated as an add-on therapy for patients with Dravet Syndrome. The research populations focused mainly on children and adolescents who continued to experience drug-resistant seizures.

Researchers primarily examined the change in the Monthly Convulsive Seizure Frequency (MCSF). Studies reported data show patterns related to changes in the measured MCSF that were monitored during the controlled comparison phase. Despite the highly controlled nature of these initial trials, the follow-up durations were relatively short, spanning only a few months. Evidence is limited for outcomes beyond these short periods. Furthermore, while the research provides context, it does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

---

Evidence for use in Lennox-Gastaut Syndrome (LGS)

Controlled research for Минифаж was also conducted in Phase 3 RCTs that explored the study drug's use as an add-on treatment for seizures associated with Lennox-Gastaut Syndrome. These studies included a broader age range, spanning children, adolescents, and some adults. The main focus of this research examined outcomes specifically by tracking changes in Drop Seizure Frequency (DSF). The research highlights changes measured during the study period in DSF when comparing the treatment group to the placebo group. Results apply only to the populations studied, and data for certain groups, particularly those at the upper end of the adult age range, remain insufficient.

---

Long-Term Research and Follow-up

To gain a clearer understanding of how the study substance was associated with symptom patterns over time, patients participated in long-term Open-Label Extension (OLE) studies, sometimes for up to three years or more. This section summarizes what is known about outcomes tracked over extended periods and describes how outcomes evolved over the extended observation periods. However, because these long-term studies are open-label (meaning both doctors and patients know who is receiving the study substance), they are generally viewed differently than the initial double-blind RCTs. Long-term effects are not fully established through controlled research.

Common questions about Минифаж (FAQ)

Q: Is Минифаж the same as other similar treatments?

Минифаж contains the active substance Fenfluramine, which is classified as an Antiepileptic Drug (AED). Its action involves modulating the serotonergic system, which is a differentiating characteristic compared to some other treatments. The medication is uniquely formulated as an oral solution, which is a key characteristic noted in the composition details.

Q: Does Минифаж cause weight gain?

Official product information indicates that decreased appetite and decreased weight are common adverse reactions reported in clinical studies. Patients using this medication are often monitored by a healthcare professional to track their weight over the course of treatment.

Q: Is it normal to feel tired after starting Минифаж?

Yes, regulatory documents list somnolence, sedation, lethargy, and fatigue as common adverse reactions documented in clinical trials. These effects are related to the central nervous system activity of the medicine. Patients are monitored for these reported effects.

Q: Can Минифаж be taken with common pain relievers?

The official interaction profile states that combining Минифаж with other Central Nervous System (CNS) depressants may potentiate certain side effects, like somnolence. Consulting a healthcare professional is necessary to properly review the safety of combining common non-prescription pain relievers with this medicine.

Q: What happens if I forget to take Минифаж sometimes?

The official prescribing information includes specific instructions on how to handle a forgotten dose. The recommended course of action for a missed dose is detailed in the patient counseling and administration sections of the regulatory documents.

Q: Is Минифаж safe for older adults to use?

Clinical trials for the approved uses of Fenfluramine did not include enough patients aged 65 and over to definitively determine if they respond differently than younger patients. Official labeling states that dose adjustments are typically considered for older adults due to the higher frequency of decreased organ function.

Q: Can women who are planning pregnancy use Минифаж?

Official information indicates there is not enough adequate data on the developmental risks of using Fenfluramine during pregnancy. Regulatory authorities state that the use of effective contraception is recommended for women of childbearing potential during treatment. Consultation with a healthcare provider is noted as necessary for addressing pregnancy planning.

Q: Can I drive or operate machinery while using Минифаж?

Regulatory safety information states that driving or operating complex machinery is typically avoided by patients. This guidance is in place until the individual has sufficient experience with Минифаж to determine if it affects their ability to perform these tasks, due to the risk of somnolence (drowsiness) and sedation.

Q: Is Минифаж a habit-forming medicine?

Fenfluramine has historically been noted as having a low potential for abuse or dependence, and the previous classification of the drug as a controlled substance has been removed by the DEA in the United States. The official product information includes a section describing its abuse potential.

Q: Does taking Минифаж affect blood pressure?

Yes, official safety information indicates that Fenfluramine can cause an increase in blood pressure. Because of this, patients' blood pressure is typically monitored during the course of treatment. Official prescribing information describes dose reduction or discontinuation as potential management steps if a sustained increase is observed.

Q: Is there a maximum time someone can stay on Минифаж?

There is no maximum duration specified in regulatory documents; treatment is generally considered a continuous, long-term approach. However, its use is managed under a mandatory Controlled Access Program, which requires patients to undergo periodic cardiac monitoring (echocardiograms) every 6 to 12 months for as long as they continue using the medication.

Q: What are the rules about using Минифаж with dietary supplements?

Official warnings note that certain dietary supplements may interact with Fenfluramine, particularly those that affect the serotonin system or influence certain liver enzymes (CYP inhibitors). Official sources note that these interactions may require the evaluation of a dosage adjustment or the avoidance of co-administration. Official guidance stresses the importance of informing the doctor about all dietary supplements being taken.

Q: Is the mechanism of action of Минифаж fully understood?

The mechanism by which Fenfluramine reduces seizure frequency is thought to be related to its ability to modulate the serotonergic system. Official scientific descriptions indicate that the exact and complete mechanisms of its therapeutic effect are not fully understood at a molecular level.

Q: Is there a list of ingredients in Минифаж besides the active substance?

Yes, the prescribing information includes a detailed description of the product. This section lists the inactive ingredients (excipients), such as coloring agents and preservatives, used in the oral solution formulation.

Q: How long does Минифаж stay in your system after you stop taking it?

According to the pharmacokinetics data found in official documentation, the elimination half-life of the drug is approximately 20 hours in healthy individuals. The half-life describes the time it takes for half of the dose to be cleared from the system.

Q: Can men use Минифаж if they are trying to conceive a child?

Nonclinical toxicology studies suggest that Fenfluramine did not cause effects on male fertility at doses considered clinically relevant. Consultation with a healthcare provider is recommended for individuals considering conception.

Q: Are there any common over-the-counter medicines that interact with Минифаж?

The official interaction profile warns that concomitant use with other Central Nervous System (CNS) depressants or serotonergic drugs may increase the risk of certain adverse reactions. Official guidance emphasizes the importance of consulting with a healthcare professional to confirm the safety of using any over-the-counter medicine.

Q: Does Минифаж cause changes in mood or behavior?

Official labeling for this medicine, like other Antiepileptic Drugs (AEDs), includes a warning about the increased risk of suicidal thoughts or behavior. Regulatory documents state that monitoring for the emergence or worsening of depression, suicidal ideation, or any unusual changes in mood or behavior is required.

Q: Is it necessary to have certain tests before starting Минифаж?

Yes, as mandated by the Controlled Access Program, patients must undergo specific tests before starting treatment. This includes obtaining a baseline echocardiogram to evaluate heart health and exclude pre-existing valvular heart disease or pulmonary hypertension.

Q: Can I split or crush the Минифаж tablet/capsule?

Минифаж is supplied only as an oral solution, not as a tablet or capsule, correcting a common user misconception. The official administration guidance specifies the need for accurate measurement of the liquid form.

Q: Is Минифаж a new drug or has it been around for a while?

The active substance, Fenfluramine, was previously marketed for a different use (obesity) but was withdrawn from the market due to safety concerns. The current formulation and regulatory approval for use in specific epilepsy syndromes are recent, based on new clinical studies.

Q: Is the effectiveness of Минифаж consistent across different age groups?

Clinical trials demonstrated effectiveness in patients aged 2 years and older. However, the data collected from certain age ranges, particularly older adult groups, is limited. The overall assessment of effectiveness is based on the combined response patterns observed across the studied populations.

Q: Does Минифаж interact with herbal remedies like St. John's Wort?

Official warnings advise caution regarding herbal remedies that have serotonergic properties (meaning they increase serotonin). Combining these with Fenfluramine may increase the risk of Serotonin Syndrome. Official guidance stresses the importance of consulting with a healthcare provider before using any herbal products.

Q: Is there a link between long-term Минифаж use and any specific health marker?

Yes, the regulatory information includes a warning about the risk of valvular heart disease (VHD) and pulmonary arterial hypertension (PAH). The Controlled Access Program mandates ongoing monitoring of these specific health markers through regular echocardiograms for the entire duration of use.

How to Store and Dispose of Minifage (Fenfluramine)

Minifage oral solution must be stored and handled according to official regulatory specifications to maintain its stability and ensure safety.

Storage Requirements

The medicine requires storage at room temperature, typically between 15°C and 30°C (59°F and 86°F), and must be protected from excessive heat and moisture. It is strictly required to not refrigerate and not freeze the solution. The medication must be kept in its original container, which should remain tightly closed.

Stability and Child Safety

Once the bottle is opened, any unused solution must be discarded after 3 months (90 days). For child safety, the product must be stored in a safe location that is entirely out of the sight and reach of children.

Disposal Instructions

Expired or unused solution should be disposed of via an authorized drug take-back program. If a program is unavailable, the disposal must follow the official household procedures, ensuring the product does not enter wastewater.